RNA Methylation and Tumor Occurrence
DOI:
https://doi.org/10.62051/ijphmr.v2n1.13Keywords:
RNA methylation, N6 methyladenosine (m6A), Tumor, Gene expression regulationAbstract
RNA methylation is a post-transcriptional modification involving the addition of methyl groups to RNA molecules, playing a crucial role in gene expression regulation. Recent studies have highlighted the importance of RNA methylation, particularly N6-methyladenosine (m6A) modification, in cancer development and progression. RNA methylation affects mRNA stability, splicing, transport, and translation, thereby regulating various aspects of tumor cell biology, including proliferation, migration, and apoptosis. Abnormal RNA methylation patterns are closely linked to tumor aggressiveness and drug resistance, with dysregulation of methylation writers, erasers, and readers contributing to cancer onset and progression. Moreover, RNA methylation plays a significant role in cancer immunotherapy by influencing tumor cell immune evasion, offering new therapeutic targets. Future research should focus on elucidating the specific mechanisms of RNA methylation in different cancer types and its interactions with the tumor microenvironment. As technologies advance, RNA methylation modulators hold promising potential for cancer treatment, providing new strategies and therapeutic targets.
References
[1] Jia G, Fu Y E, Zhao X U, et al. N 6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO [J]. Nature chemical biology, 2011, 7(12): 885-887.
[2] Shao C, Han Y, Huang Y, et al. Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy [J]. International Journal of Oncology, 2023, 64(2): 17.
[3] Song S, Fan G, Li Q, et al. IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma [J]. Oncogene, 2021, 40(35): 5393-5402.
[4] Zeng P, Lu W, Tian J, et al. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy [J]. Journal of hematology & oncology, 2022, 15(1): 30.
[5] Farooqi A A, Fayyaz S, Poltronieri P, et al. Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs[C]//Seminars in cancer biology. Academic Press, 2022, 83: 197-207.
[6] Hayat R, Manzoor M, Hussain A. Wnt signaling pathway: A comprehensive review [J]. Cell biology international, 2022, 46(6): 863-877.
[7] Song S, Fan G, Li Q, et al. IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma [J]. Oncogene, 2021, 40(35): 5393-5402.
[8] Si C, Chen C, Guo Y, et al. Effect, mechanism, and applications of coding/non-coding RNA m6A modification in tumor microenvironment [J]. Frontiers in Cell and Developmental Biology, 2021, 9: 711815.
[9] Zhang L, Xia J. N6-Methyladenosine Methylation of mRNA in Cell Apoptosis [J]. Molecular Neurobiology, 2024, 61(7): 3934-3948.
[10] Zhang S. Mechanism of N6-methyladenosine modification and its emerging role in cancer [J]. Pharmacology & Therapeutics, 2018, 189: 173-183.
[11] Chi H C, Tsai C Y, Tsai M M, et al. Roles of long noncoding RNAs in recurrence and metastasis of radiotherapy-resistant cancer stem cells [J]. International journal of molecular sciences, 2017, 18(9): 1903.
[12] Wang X, Lu Z, Gomez A, et al. N 6-methyladenosine-dependent regulation of messenger RNA stability [J]. Nature, 2014, 505(7481): 117-120.
[13] Wang S, Lv W, Li T, et al. Dynamic regulation and functions of mRNA m6A modification [J]. Cancer cell international, 2022, 22(1): 48.
[14] He Y, Yue H Q, Cheng Y, et al. ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling [J]. Cell death & disease, 2021, 12(12): 1121.
[15] Wang Z, Zhou J, Zhang H, et al. RNA m6A methylation in cancer [J]. Molecular Oncology, 2023, 17(2): 195-229.
[16] Tang B, Yang Y, Kang M, et al. m 6 A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling [J]. Molecular cancer, 2020, 19: 1-15.
[17] Han H, Fan G, Song S, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL [J]. Blood, The Journal of the American Society of Hematology, 2021, 137(12): 1603-1614.
[18] Chen Z, Hu Y, Jin L, et al. The emerging role of N6-methyladenosine RNA methylation as regulators in cancer therapy and drug resistance [J]. Frontiers in pharmacology, 2022, 13: 873030.
[19] Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling [J]. Cell, 2018, 172(1): 90-105. e23.
[20] Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA [J]. Cell research, 2017, 27(3): 315-328.
[21] Gong P J, Shao Y C, Yang Y, et al. Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer [J]. Frontiers in oncology, 2020, 10: 578963.
[22] Wan W, Ao X, Chen Q, et al. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer [J]. Molecular cancer, 2022, 21(1): 60.
[23] Li H, Wu H, Wang Q, et al. Dual effects of N6-methyladenosine on cancer progression and immunotherapy [J]. Molecular Therapy-Nucleic Acids, 2021, 24: 25-39.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
